What is HC Wainwright’s Forecast for APRE FY2026 Earnings?

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Analysts at HC Wainwright raised their FY2026 EPS estimates for Aprea Therapeutics in a research report issued on Thursday, January 29th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.98) per share for the year, up from their previous forecast of ($1.21). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($1.03) EPS.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%.The firm had revenue of $0.00 million for the quarter.

A number of other analysts also recently weighed in on APRE. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Zacks Research downgraded Aprea Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Aprea Therapeutics has a consensus rating of “Hold” and an average target price of $7.50.

Aprea Therapeutics Trading Down 10.3%

NASDAQ APRE opened at $0.67 on Monday. The stock has a market capitalization of $4.71 million, a price-to-earnings ratio of -0.31 and a beta of 1.48. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.31. Aprea Therapeutics has a 12-month low of $0.55 and a 12-month high of $4.65.

Insider Buying and Selling

In other news, Director Marc Duey bought 21,459 shares of the stock in a transaction on Wednesday, December 10th. The shares were bought at an average price of $1.17 per share, with a total value of $25,107.03. Following the completion of the acquisition, the director owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. This trade represents a 9.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.63% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.